Goldman Sachs’s Immunic IMUX Stock Holding History

Goldman Sachs’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-750	Closed	-$1.21M	–	7240
2015 Q3	$1.21M	Buy	750 +250	+50%	+$1.25M	﹤0.01%	4282
2015 Q2	$4.22M	Buy	+500	New	+$4.77M	﹤0.01%	3110

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Goldman Sachs's IMUX Position: Q2 2026 in Review

Goldman Sachs sold out of Immunic (IMUX) in Q2 2026, closing a stake of 14,977 shares — an estimated $166K sold.

Goldman Sachs first reported a position in IMUX in Q2 2014 and held it in 31 quarters. The position peaked at $2.78M in Q1 2022. 56 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

Goldman Sachs reported no remaining Immunic position as of Q2 2026 after selling out during the quarter.
Goldman Sachs sold 14,977 Immunic shares in Q2 2026, an estimated $166K.
Goldman Sachs first reported a position in Immunic in Q2 2014 and held it in 31 quarters.
Goldman Sachs's Immunic position peaked at $2.78M in Q1 2022.
56 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.